NTRR
Neutra Corp.0.0001
+0.0001+50%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
437.69KP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q1 FY2025 results
Neutra Corp. posted Q1 FY2025 revenue of $32,375, up sharply from $5,842 y/y, fueled by $29,420 in business development consulting while CBD product sales ticked to $2,955. Gross margin soared to 95.6% from 48.0%, yet operating expenses fell to $46,440, trimming the operating loss to $15,485 from $71,208 y/y. Net loss narrowed further to $16,352, matching via minor interest expense. Cash dwindled to $333 with $1,299 used in operations (derived); liabilities hit $987K against scant assets, signaling distress. Related-party note in default. Controls ineffective. Going concern in doubt.
10-K
FY2024 results
Neutra Corp posted FY2024 revenue of $39,534, down 42% y/y from $67,996, with gross margin shrinking to $14,335 amid $25,199 COGS; operating loss narrowed to $229,486 from $297,675 as G&A fell to $187,123, mainly from lower consulting and marketing plus employee retention credits. Net loss improved to $233,465 versus $561,417, helped by interest expense dropping to $3,340 after debt conversions—no Q4 breakdown disclosed in the 10-K. Cash dwindled to $1,632 with $10,337 negative operating cash flow, funded by related-party advances; working capital deficit hit $971,799. No dividends or buybacks. Regulatory crackdowns on delta-8-THC products threaten sales momentum.
8-K
Auditor switch after ban
10-Q
Q1 FY2024 results
Neutra Corp's Q1 FY2024 revenue plunged 94% y/y to $1,311 from $23,383, with gross margin shrinking to 45% from 46%, yet operating loss narrowed to $52,728 from $66,074 on lower depreciation and G&A. Nine-month revenue fell 82% y/y to $11,478, driving net loss to $198,829 from $286,414, mainly from reduced interest expense after convertible note settlements. Cash dwindled to $692, with operating cash use at $11,277 offset by $10,000 related-party advance; related-party note of $54,156 at 6% remains past maturity. Series G preferred fully converted to common. Disclosure controls falter on related-party tracking.
10-Q
Q2 FY2024 results
Neutra Corp's Q2 revenue slid 85% y/y to $4,325 while gross margin held at 39% (derived), yet operating loss narrowed to $71,769 from $82,350 thanks to lower sales commissions and G&A. Six-month revenue fell 74% y/y to $10,167, with net loss shrinking to $143,843 from $204,622; operating loss tracks closely as interest expense dropped sharply. Cash dwindled to $1,134 amid $10,835 operating outflow, offset by $10,000 related-party advance, leaving negative working capital of $843,493 and $54,156 related-party note past maturity. Series G preferred fully converted to common. Going concern in doubt. Disclosure controls remain ineffective.
IPO
Website
Sector
Industry
CNTMF
FLUENT CORP
0.07+0.01
CRON
Cronos Group Inc. Common Share
3.16+0.11
EDXC
ENDEXX Corp.
0.00+0.00
HSTI
High Sierra Technologies Inc.
1.40+0.00
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
NXEN
Nexien BioPharma, Inc.
0.00+0.00
NXGB
NxGen Brands Inc.
0.00-0.00
TSNDF
TerrAscend Corp.
1.13+0.23
XTXXF
ADASTRA HOLDINGS LTD
0.02+0.00
YCBD
cbdMD, Inc.
1.43+0.23